About: Proceedings of a Consensus Conference: Pathogen Inactivation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Proceedings of a Consensus Conference: Pathogen Inactivation—Making Decisions About New Technologies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Proceedings of a Consensus Conference: Pathogen Inactivation—Making Decisions About New Technologies
Creator	Lin, Yulia Hannon, Judy Pavenski, Katerina Blajchman, Morris Cserti, Christine Pendergrast, Jacob Webert, Kathryn
Source	Elsevier; Medline; PMC
abstract	Significant progress has been made in reducing the risk of pathogen transmission to transfusion recipients. Nonetheless, there remains a continuing risk of transmission of viruses, bacteria, protozoa, and prions to recipients. These include many of the viruses for which specific screening tests exist as well as pathogens for which testing is currently not being done, including various species of bacteria, babesiosis, variant Creutzfeld-Jacob disease, hepatitis A virus, human herpes virus 8, chikungunya virus, Chagas disease, and malaria. Pathogen inactivation (PI) technologies potentially provide an additional way to protect the blood supply from emerging agents and also provide additional protection against both known and as-yet-unidentified agents. However, the impact of PI on product quality and recipient safety remains to be determined. The purpose of this consensus conference was to bring together international experts in an effort to consider the following issues with respect to PI: implementation criteria; licensing requirements; blood service and clinical issues; risk management issues; cost-benefit impact; and research requirements. These proceedings are provided to make available to the transfusion medicine community the considerable amount of important information presented at this consensus conference.
has issue date	2008-01-31(xsd:dateTime)
bibo:doi	10.1016/j.tmrv.2007.09.001
bibo:pmid	18063190
has license	els-covid
sha1sum (hex)	9513e5e2604d11e0aa4fc5b68572696f780e28ca
schema:url	https://doi.org/10.1016/j.tmrv.2007.09.001
resource representing a document's title	Proceedings of a Consensus Conference: Pathogen Inactivation—Making Decisions About New Technologies
has PubMed Central identifier	PMC7127103
has PubMed identifier	18063190
schema:publication	Transfusion Medicine Reviews
resource representing a document's body	covid:9513e5e2604d11e0aa4fc5b68572696f780e28ca#body_text
is schema:about of	named entity 'New Technologies' named entity 'CONSENSUS' named entity 'NEW TECHNOLOGIES' named entity 'PROCEEDINGS' named entity 'ABOUT' named entity 'PATHOGEN' named entity 'CONFERENCE' named entity 'INACTIVATION' named entity 'MAKING DECISIONS' named entity 'Pathogen Inactivation' named entity 'CONSENSUS CONFERENCE' named entity 'CONSENSUS CONFERENCE' named entity 'Making Decisions' named entity 'Consensus Conference' named entity 'Proceedings' named entity 'Pathogen' named entity 'EVIEWS' named entity 'About'
is part of of	Significant progress has been made in reducing the risk of pathogen transmission to transfusion recipients. Nonetheless, there remains a continuing risk of transmission of viruses, bacteria, protozoa, and prions to recipients. These include many of the viruses for which specific screening tests exist as well as pathogens for which testing is currently not being done, including various species of bacteria, babesiosis, variant Creutzfeld-Jacob disease, hepatitis A virus, human herpes virus 8, chikungunya virus, Chagas disease, and malaria. Pathogen inactivation (PI) technologies potentially provide an additional way to protect the blood supply from emerging agents and also provide additional protection against both known and as-yet-unidentified agents. However, the impact of PI on product quality and recipient safety remains to be determined. The purpose of this consensus conference was to bring together international experts in an effort to consider the following issues with respect to PI: implementation criteria; licensing requirements; blood service and clinical issues; risk management issues; cost-benefit impact; and research requirements. These proceedings are provided to make available to the transfusion medicine community the considerable amount of important information presented at this consensus conference. covid:9513e5e2604d11e0aa4fc5b68572696f780e28ca#body_text Proceedings of a Consensus Conference: Pathogen Inactivation—Making Decisions About New Technologies

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software